USA300 poses diagnostic surveillance challenge in US - now also "UK on alert"
This article was originally published in Clinica
USA300, a clone of the methicillin-resistant Staphylococcus aureus (MRSA) bacterium that is already at the centre of the international war on hospital-acquired bloodstream infections, is emerging in the US as a major challenge in the community setting too.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.